5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans
- PMID: 7117789
5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans
Abstract
The release pattern, bioavailability, and kinetics of a 5-aminosalicylic acid tablet with sustained release were studied in humans. Six ileostomy patients received a single dose (500 mg). Eight and 48 h later, respectively, 58% and 65% of the dose was recovered in the ileostomy effluents, either as 5-aminosalicylic acid still retained in the preparation, free 5-aminosalicylic acid or acetyl-5-aminosalicylic acid. Fourteen healthy volunteers took 1500 mg of 5-aminosalicylic acid per day for 6 days and a steady state plasma acetyl-5-aminosalicylic acid concentration was reached on day 5 (1.1-2.9 microgram/ml). 5-Aminosalicylic acid was not detected in the plasma. At steady state, 40% of the 24-h dose was recovered from feces, and 53% from the urine. The sustained-release preparation studied provides sufficient amounts of 5-aminosalicylic acid to all parts of the gut and its curative effect in ulcerative colitis and Crohn's disease should be examined in controlled trials.
Similar articles
-
A new slow-release form of 5-aminosalicylic acid for the oral treatment of inflammatory bowel disease. Biopharmaceutic and clinical pharmacokinetic characteristics.Arzneimittelforschung. 1985;35(3):636-9. Arzneimittelforschung. 1985. PMID: 4039590
-
5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.Dan Med Bull. 2000 Feb;47(1):20-41. Dan Med Bull. 2000. PMID: 10709142 Review.
-
Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.Aliment Pharmacol Ther. 2004 May 15;19(10):1089-98. doi: 10.1111/j.1365-2036.2004.01964.x. Aliment Pharmacol Ther. 2004. PMID: 15142198 Clinical Trial.
-
Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.Z Gastroenterol. 1996 Apr;34(4):225-9. Z Gastroenterol. 1996. PMID: 8686349 Clinical Trial.
-
Chemistry, pharmacology, pharmacokinetics, and clinical applications of mesalamine for the treatment of inflammatory bowel disease.Pharmacotherapy. 1994 Jul-Aug;14(4):385-98. Pharmacotherapy. 1994. PMID: 7937276 Review.
Cited by
-
Formulation and characterization of 5-Fluorouracil enteric coated nanoparticles for sustained and localized release in treating colorectal cancer.Saudi Pharm J. 2015 Jul;23(3):308-14. doi: 10.1016/j.jsps.2014.11.010. Epub 2014 Dec 11. Saudi Pharm J. 2015. PMID: 26106279 Free PMC article.
-
Sulfasalazine. Multiplicity of action.Dig Dis Sci. 1992 Jun;37(6):801-12. doi: 10.1007/BF01300376. Dig Dis Sci. 1992. PMID: 1350243 Review. No abstract available.
-
Release of 5-aminosalicylic acid from Pentasa during normal and accelerated intestinal transit time.Br J Clin Pharmacol. 1987 Mar;23(3):365-9. doi: 10.1111/j.1365-2125.1987.tb03061.x. Br J Clin Pharmacol. 1987. PMID: 3567055 Free PMC article.
-
Diagnosis by Microbial Culture, Breath Tests and Urinary Excretion Tests, and Treatments of Small Intestinal Bacterial Overgrowth.Antibiotics (Basel). 2023 Jan 28;12(2):263. doi: 10.3390/antibiotics12020263. Antibiotics (Basel). 2023. PMID: 36830173 Free PMC article. Review.
-
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.Drugs. 2000 Apr;59(4):929-56. doi: 10.2165/00003495-200059040-00016. Drugs. 2000. PMID: 10804042 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources